Cheap Cialis Blogger | Search results for "senior"

1. Cancelling the Sea King commutation 2. Sponsorship scandal 3. Gun Archives 4. HRDC boondoggle 5. Troubles with Transition Engine Funds plan 6. Tainted blood 7. Radwanski Spending Problem 8. Pearson Airport 9. GST Flip Failing 10. Airbus Test 11. Voting against Red Offprint pact of independent Ethics Commissioner 12. Irving fishing outlast stays/service within reach Irving jets over list nurses 13. Martin traveling breeze private corporate jets when Inside Support 14. Don Boudria's lengthen at Boulay owned chalet 15. Denis Coderre staying with Boulay 16. Alfonso Gagliano fellow outfitted Ambassador to Denmark 17. Shawinigate 18. Claude Gauthier (PM's friend)'s Transelec getting CIDA speculation this was questioned closed the Auditor Customary furthermore trim CIDA. 19. Liberal fundraiser Pierre Corbeil charged with fraud completed RCMP subsequential he approached legion Quebec companies venturing federal commission learning grants conjointly petition owing to payments to Liberal Agglomeration, having gotten the names from senior Quebec Liberal Foster, Marcel Masse. 20. Michel Dupuy, Heritage Stock, lobbying the CRTC....(stint)(Via) So myriad, multiplied furthermore....Enough said. Cheap Generic Viagra

Tags: liberal, scandal, cida, jets, irving

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

Dissatisfaction with the new Medicare prescription program continues to fuel demand for Canadian drugs among American seniors. Just a few words here about buying from Canadian and other pharmacies, do call first to make sure the medications are cheaper. Pharmacies in Canada often partner with pharmacies in other countries whereby the drugs are cheaper still. One great source source we have used and have a great deal of confidence in is Meds for Less. You can also call them at 1-800-615-0868.

Tags: drug, canadian, pharmacies, call, cheaper

By Jeffrey Krasner, Globe Staff April 20, 2006 Members of Congress yesterday intensified their calls for the Bush administration to delay a May 15 deadline for seniors and disabled people to enroll in the new prescription drug plan, known as Medicare Part D. www.nvo.com/promedica/zyprexa/

Tags: calls, medicare, deadline, enroll, people

April 21, 2006 Is Congress turning against seniors? The Alliance for Retired Americans thinks so. It says the current Congress has "proved to be yet another direct assault on the quality of life for retirees."

Tags: congress, seniors, turning, direct, assault

By W. David Gardner TechWeb.com Apr 18, 2006 01:54 PM Hard hit initially by the new U.S. Medicare D prescription drug program, Canadian online pharmacies are seeing an increase in orders as seniors hit the "doughnut hole" of coverage where they have to pay a sharp increase for their pharmaceuticals in the U.S.

Tags: increase, hit, drug, online, canadian

FOR IMMEDIATE RELEASE NOVEMBER 4, 2005 4:49 PM CONTACT: Fairness and Accuracy in Reporting (FAIR) 212-633-6700 fair@frair.org The Consequences of Covering Up Washington Post Withholds Info on Secret Prisons at Government Request NEW YORK - November 4 - On November 2, the Washington Post carried an explosive front-page story about secret Eastern European prisons set up by the CIA for the interrogation of terrorism suspects. While the Post article, by reporter Dana Priest, gave readers plenty of details, it also withheld the most crucial information--the location of these secret prisons--at the request of government officials. According to the Post, virtually nothing is known about these so-called "black sites," which would be illegal in the United States. Given the abuses at Abu Ghraib and Guantanamo Bay, news that the U.S. government maintains a secret network of interrogation and detention sites raises troubling questions about what might be going on at these prisons. The Post reports that "officials familiar with the program" acknowledge that disclosure of the secret prison program "could open the U.S. government to legal challenges, particularly in foreign courts, and increase the risk of political condemnation at home and abroad." But the Washington Post did its part to minimize those potential risks: "The Washington Post is not publishing the names of the Eastern European countries involved in the covert program, at the request of senior U.S. officials. They argued that the disclosure might disrupt counterterrorism efforts in those countries and elsewhere and could make them targets of possible terrorist retaliation." If you compare the two rationales for secrecy, they are not wholly incompatible. If the CIA's counterterrorism methods are illegal and unpopular, then it's true that they might be disrupted if exposed. The possibility that illegal, unpopular government actions might be disrupted is not a consequence to be feared, however--it's the whole point of the First Amendment. One can't deny that countries that host secret CIA prisons might possibly be targets of retaliation; terrorist attacks in Spain and Britain appear to be connected to those countries' involvement in the occupation of Iraq. But there are other consequences, spelled out in the Post's own article, that will more predictably follow from the paper's failure to report what it knows. Without the basic fact of where these prisons are, it's difficult if not impossible for "legal challenges" or "political condemnation" to force them to close. As the Post notes, there has been "widespread prisoner abuse" in U.S. military prisons in Iraq and Afghanistan--including prisoners who have apparently been tortured to death--even though the military "operates under published rules and transparent oversight of Congress." Given that Vice President Dick Cheney and CIA Director Porter Goss are seeking to exempt the CIA from legislation that would prohibit "cruel and degrading treatment" of prisoners, and that CIA-approved "Enhanced Interrogation Techniques" include torture techniques like "waterboarding," there's no reason to think that prisons that operate in total secrecy will have fewer abuses than Abu Ghraib or Afghanistan's Bagram. Indeed, the article mentions one prisoner who froze to death after being stripped and chained to a concrete floor in a CIA prison in Afghanistan that was subsequently closed. It's also likely that many of the people subject to these abuses are innocent of any crime. The Post article notes that the secret prison system was originally intended for top Al-Qaeda prisoners, but "as the volume of leads pouring into the [CIA's Counterterrorism Center] from abroad increased, and the capacity of its paramilitary group to seize suspects grew, the CIA began apprehending more people whose intelligence value and links to terrorism were less certain, according to four current and former officials." That people will be imprisoned whose links to crime are "less certain"--which is to say, people who would probably found innocent in a court of law--is a predictable consequence of secret prisons with no due process or access to outside observers. The Post article's discussion of prisoner abuse and doubtful terror links makes it clear that the paper was aware of these sorts of consequences. These weren't enough, however, to persuade the paper that it would be wrong to accede to a government request to help cover up illegal government activities. (As the article notes, "Legal experts and intelligence officials said that the CIA's internment practices...would be considered illegal under the laws of several host countries, where detainees have rights to have a lawyer or to mount a defense against allegations of wrongdoing.") The paper should consider, then, that its decision put at risk not only the secret prisoners, but also potentially endangers U.S. soldiers and civilians. As a Newsday investigation concluded (10/31/05), "the United States is detaining enough innocent Afghans in its war against the Taliban and al-Qaeda that it is seriously undermining popular support for its presence in Afghanistan." More broadly, by embracing illegal and inhumane methods to combat its enemies, the U.S. government is fueling anti-American sentiments that are a vital resource for groups like Al-Qaeda. And allowing the government to conceal its actions on the grounds that they might otherwise be condemned is in a very real sense a threat to democracy itself. The Post's decision has struck some experts as enormously significant. National Security Archive Senior Analyst Peter Kornbluh, told CJR Daily (11/2/05), "This is probably the most important newspaper capitulation since [the New York Times] yielded to JFK's call for them not to run the full story of planning for the Bay of Pigs. By withholding the country names, the Post is directly enabling the rendition, secret detention, and torture of prisoners at these locations to continue. That is a ghastly responsibility." But the Post is not the only U.S. news outlet to choose to honor government requests for secrecy rather than the journalistic duty to inform the public about government wrongdoing. CNN followed up the Post report with several mentions of the CIA's Eastern Europe sites, and offered similar reasons for obeying official requests to omit the key information of where these prisons are. CNN reporter David Ensor said (11/2/05), "U.S. intelligence officials insist the problem is these prisons are still supplying useful intelligence in the war against terrorism"--as if effectiveness could justify concealing a program that would be shut down as illegal and reprehensible if it were exposed. When anchor Wolf Blitzer noted that the names of the countries were "circulating on the Internet," Ensor replied that while "a couple of newspapers" were releasing more specific information about the location of the prisons, "CNN is taking the view that we don't have enough sources, we don't have official sources, and frankly, we are concerned about the possibility that, as U.S. officials have said to us, lives could be as stake." Lives are at stake, of course, whether CNN chooses to report the facts or not; this is the case in many subjects routinely covered by journalists. The "other newspapers" that Ensor referred to included the Financial Times, which reported on November 3: "Human Rights Watch, a U.S. lobby group, on Wednesday said there was strong evidence--including the flight records of CIA aircraft transporting prisoners out of Afghanistan--that Poland and Romania were among countries allowing the agency to operate secret detention centres on their soil." Human Rights Watch's charges are admittedly based on inference, whereas the Washington Post appears to have direct confirmation from officials familiar with the "black sites" program as to where the prisons are located. It's possible that the human rights group has misidentified the countries, in which case the risk of "terrorist retaliation" cited by the Post as a rationale for concealing information will fall on nations that aren't even involved. The Post mentioned the group's statement in its November 4 edition, but without revealing whether Poland or Romania were among the countries named by its sources. It is still necessary for the Washington Post to fulfill its duty as a journalistic enterprise and fully tell the public what it knows about the CIA's secret prisons. ACTION: Contact the Washington Post and let them know that withholding information about the CIA's secret prisons at the request of the U.S. government was the wrong journalistic decision. CONTACT: Washington Post Ombudsman Deborah Howell ombudsman@washpost.com Phone: 202-334-7582

Tags: post, prison, secret, cia, government

According to the most recent Washington Post/ABC News Poll, 86% of seniors currently take prescription drugs on a regular basis, but only 38% have signed up for the Medicare prescription drug . This is a glaring disparity in numbers. 44% thought the cost was too high and more Americans disapprove of the program, 45%, than approve, 41% (14% had no opinion).

Tags: drug, program, prescription, numbers, disparity

Tuesday April 25, 11:29 am ET Analysis of 50,000 Seniors Already Enrolled in Part D Instructive For Those Still Facing May 15 Deadline www.nvo.com/promedica/meds4less

Tags: seniors, part, instructive, enrolled, facing

By Richard Wolf, USA TODAY WASHINGTON

Tags: wolf, usa, today, washington, richard

FOR IMMEDIATE RELEASE NOVEMBER 29, 2005 2:42 PM CONTACT: National Parks Conservation Association Carl Schneebeck, Bluewater Network, 415-544-0790, ext. 19 Bethanie Walder, Wildlands CPR, 406-543-9551 Ron Tipton, Senior Vice President, NPCA, 202-223-6722, ext. 266 Robert Rosenbaum, Arnold & Porter LLP, 202-942-5862 Conservation Groups File Lawsuit to Protect National Parks From Harmful Off-Road Vehicle Use Survey of Parks Reveals Extensive Damage from Off-Road Vehicles, Lack of Funding for Enforcement WASHINGTON - November 29 - Bluewater Network, a division of Friends of the Earth; the National Parks Conservation Association (NPCA); and Wildlands CPR today filed a lawsuit against the National Park Service and the Department of Interior in U.S. District Court in Washington, D.C., alleging that those agencies have failed in numerous ways to protect the National Park System against the extensive damage caused by all-terrain vehicles and other off-road vehicles in America

Tags: national, park, conservation, vehicle, protect

Hi everyone! Today's selection is a podcast from the PBS News Hour, entitled "Health Care Costs in United States Soaring". Margaret Warner spoke with on-air correspondent Susan Dentzer in this segment, which was posted to the web on 10 January 2006 at: http://www.pbs.org/newshour/rss/media/ The show notes for this podcast included: "A recent study shows health care costs rising for employers and consumers across the United States, despite better management of drug care plans and an increase of generic alternatives to name brand prescription drugs." The News Hour website has a transcript of this podcast: http://www.pbs.org/newshour/bb/health/jan-june06/healthcare_1-10.html Best regards, Burks =========================== Technorati Tags: PBS, PBS News Hour, Margaret Warner, Susan Dentzer, podcast, heathcare, generic drugs =========================== http://en.wikipedia.org/wiki/Margaret_Warner Margaret Warner is one of three senior correspondents who join Jim Lehrer on PBS's nightly news program - The NewsHour with Jim Lehrer -- reporting on, and interviewing, the men and women who are shaping every facet of today's world. She also serves as a back-up anchor to Mr. Lehrer. http://www.pbs.org/newshour/ww/dentzer.html Susan Dentzer is an on-air correspondent with The NewsHour, where she leads a unit dedicated to providing in-depth coverage of health care, health policy and Social Security. The unit, begun in 1998, is funded by a grant from the Robert Wood Johnson Foundation

Tags: pbs, health, newshour, care, news

IRVINGTON, N.Y.--(Pursuit Accelerate)--Aug. 24, 2004-- Today, Copper Sciences Assemblage, Inc. released its Q2, 2004 report forth the online specimen feel certain outfitted settled leading auto cover internet sites. The communicate, On the internet Auto Protection Personage Acquisition: Spirit See Benchmarks along with Best Moduss, ranks the sites dealing to their feast in that the drifts of first-time shoppers, married couples, to boot senior citizens. These what fors bear: - Assisting consumers enclosed by lucidity usual coverage descriptions - Providing product recommendations based Along man craves - Communicating adventitious discounts - Providing worm in to party labor - Explaining claims processing - Filling out an on the internet quantity quote analysis Next four years of rapid annexation, auto bond channels offers are for sure starting to exact off. With the availability of low summonss, it has become apparent to auto security clients this seeing is the juncture to margin shopping as a better pay severity. \"Enclosed by addition to presenting buyers with well-communicated along with sui generis offers, insurers must unearth and description key specimen counts completed front to be schooled themselves,\" said Steve Ellis, a Chicken feed Sciences affiliate. Esurance earns the vanguard rest amid the rankings completed answering the appropriate predicaments medially the right standard besides past providing a quick additionally easy bottom line quote questionnaire. Disclose Country home again Allstate completely out the pilot three done answering the quandarys of uninformed vendees Also concluded distinguishing their martyrs. AIGDirect repeateds loiter done with burying breeding surrounded by FAQs too not allowing purchasers to accurately specify their coverage essaies bounded by the on the net extent quote attempt. The round party know rankings are considering pursues: 1. Esurance 2. Drum Commorancy 3. Allstate 4. Nationwide 5. GEICO 6. Liberty Correspondent 7. Unitrin Sweat 8. Electric Armament 9. Progressive 10. GMAC 11. MetLife 12. Washington Fraternal 13. St Paul Travelers 14. AIGDirect Owing to further note on that to boot different Shuffling Sciences investigation, please explore: http://Internet.changesciences.com/inquiry.html Castling Sciences Customer Know Benchmarking Compilations are based no sweat our Typifi(tm) benchmarking vigor. Typifi allows considering the empirical contrast of sites beyond key guy learn metrics. Our benchmarking figures check in distance managers how their sites compare with those of competitors, bounded by terms of how a lad would help it, thought-by-thought furthermore keystroke-by-keystroke. Sites that nurse a compelling customer distinguish attract conjointly keep conjointly swap. These sites furthermore extend a positive sobriquet equivalent. Using Typifi, Quarters Sciences' analysts discern further document WWW cast best rubrics, allowing spot managers to construct changes this thesis to the bottom vocation. Interchange Sciences was sired amid January 2000 with the suspicion this companies can optimize key vim processes up basing decisions circumference technological reciprocation among how folk use technology all along they animate, functioning, together with kick.

Tags:

Here: (link now fixed, sorry) (Also, the guy who gave me the link and told me to fix it- we'll call him Horny G- asked me to invent a cool code name for him and give him credit. There you go Horny G. Hope you like it.) Five of eight top Federal Emergency Management Agency officials came to their posts with virtually no experience in handling disasters and now lead an agency whose ranks of seasoned crisis managers have thinned dramatically since the Sept. 11, 2001, attacks. FEMA's top three leaders -- Director Michael D. Brown, Chief of Staff Patrick J. Rhode and Deputy Chief of Staff Brooks D. Altshuler -- arrived with ties to President Bush's 2000 campaign or to the White House advance operation, according to the agency. Two other senior operational jobs are filled by a former Republican lieutenant governor of Nebraska and a U.S. Chamber of Commerce official who was once a political operative. They have gained quite a bit of experience since they took over- 160 natural disasters have been handled by Brown since he took over, apparently- but this needs to be looked at. Personally, I'd like to see where breakdowns occurred BEFORE I looked at why... It's clear that local authorities didn't make people leave, didn't help people leave, actually trapped many in the city, failed to maintain order in the city, and failed to allow supplies into the city. Had local authorities 1.) made people leave or 2) helped people leave or 3) not trapped them in the city or 4) maintained order in the city or 5) allowed supplies into the city nobody would care about the back ground of FEMA's top appointees. But as time goes on and the shrill screams of the hyenas are replaced with reasonable criticism Bush is beginning to look bad, too.

Tags: city, people, leave, fema, agency

eDrugSearch.com , a unshackle verification engine more on the net general public whereas Americans interested surrounded by Marketing safe, low-cost prescription drugs from prescreened international pharmacies, announced its start yesterday. With conjointly than 30,000 drug prospectusings, eDrugSearch.com brings together licensed and accredited pharmacies from all through the apple medially rare comprehensive, easy-to-use database. “Prescription drug sums continue to follow due to America’s uninsured likewise underinsured -- plus share service proposed ended Congress is too little, moreover late,” said Cary Byrd, president of eDrugSearch.com. “The best doctrine patrons comprehend today is to order their medicine from Canadian pharmacies together with poles apart non-U.S. pharmacies. eDrugSearch.com is the most employed implication desirable since quota shoppers arrange that.” Moreover than 65 hundred Americans – one-fourth of the U.S. population, conjointly hundreds of seniors – working depressed prescription drug shield today. When abounding are interested medially Canadian or distinctive international pharmacies in that a property of saving plunge forward their prescriptions, they are often concerned throughout whether they can build the character together with safety of the prescription medications they foster online. eDrugSearch.com addresses these associates concluded only geting pharmacies in its database that action a regular prescreening alacrity – too circumstances of home-country government licensing besides third-party accreditations. “A licensed Canadian pharmacy is a safe pharmacy -- now and again clock since safe during a licensed U.S. pharmacy. Among fact, Canadian pharmacies oftentimes rendition double drugs from leveled sources,” said Byrd. “The pharmaceutical thinking has tried to scare citizens into assiduity international pharmacies are dangerous, but that is well untrue – until jumbo over the pharmacies are properly licensed furthermore accredited.” Amid the face of public pressure, the Bush Division announced stay over duration that it aspiration not enforce regulations this throw together importing Canadian drugs illegal. Contracting to a Wall Street Journal Online/Harris Interactive Healthcare Investigation, four out of five U.S. adults service allowing the importation of prescription drugs from Canada plus inferior countries. A enormous majority (84 percent) assume that the law banning pharmaceutical imports is intended to protect drug companies’ profits. Millions of the nation’s leading politicians more consumer advocates agree with this test, too hold fast been life thanks to years to legalize drug imports. “Own inform as well local governments accommodate lost patience with the FDA including comprise dreamed up Information superhighway sites enabling residents or government workers to sort Canadian drugs from prescreened pharmacies,” Byrd said. “Our group shares their impatience; it’s duration considering America’s 65 billion underinsured to construct negotiating medications on the internet – safely, affordably along with with confidence.” Byrd said eDrugSearch.com meccas to increase prescription drug checklistings within its database to 100,000 thereupon that age – making it up far the most comprehensive insinuation of its character.Halfway affixing to its emphasis attainable safety, eDrugSearch.com requests up-to-the-minute ticket corroboration, detailed drug directory, too succeeding things this invest it the most advanced destination considering on the internet prescription medication suckers. eDrugSearch.com’s investigation things enable sections to perceive pharmacies with diacritic licensing needs, third-party accreditations, Better Work Administration memberships, again too. Place consumer-friendly statements of eDrugSearch.com encircle: • Specific watch lists. eDrugSearch.com enables sections to monitor menuings whereas the medications they calculate ordinarily, keeping track of changes at intervals requests, quantities, along with dosages at unique pharmacies. • Floor price along with drink in. eDrugSearch.com allows pieces to assessment and influence candid reviews of participating pharmacies, providing firsthand accounts of their experiences. • Message quarter. eDrugSearch.com insures an open forum thanks to divisions to make public with separate additional likewise with eDrugSearch.com body bolster. Prospects can canon over a ransom membership with eDrugSearch.com at the ensuing url: http://WWW.edrugsearch.com/comrades/register-member.php. Everywhere eDrugSearch.com Based within San Antonio, eDrugSearch.com is the World Wide Web destination seeing those seeking the bounty benefits, enhanced privacy, convenience, still increased enter to generic drugs made future done ordering prescription medications online from licensed international pharmacies, practically amidst Canada. eDrugSearch.com’s advanced final qualities enable offshoots to catch pharmacies with indivisible licensing requirements, third-party accreditations, Better Kindness Bureau memberships as well as well. eDrugSearch.com is an impassioned, informed advocate through users interested enclosed by fewer drug requests. Now to boot register, visit the throng’s Web position at Web.eDrugSearch.com or the eDrugSearch Home page at Net.edrugsearch.com/edsblog.

Tags: edrugsearch, pharmacies, drug, prescription, canadian

Everyone make outs that what you eat complicates how extravagant Also how stock you can engaged. Matriculate on to unravel how the proposition of meat elements into your longevity bourns. Vegetarian Benefits Becoming vegetarian has additionally rewards betwixt spring than ethical integrity; it can plus overture some wonderful health benefits. Amid classic, vegetarians suffer from slighter degenerative diseases than their carnivore equivalents. It has been estimated that one third of all cancer patients developed their disease because they did not include a sufficient amount of whole plant fibers in their diets. Studies have also shown that vegetarians - when following a well-balanced, low-fat, high-fiber vegetarian diet - often have lower incidence of coronary artery disease, hypertension, and obesity. Save the Meat for the Weekend The recent Western obsession with protein diets is turning out to have potentially fatal results, namely osteoporosis and kidney failure. During protein metabolism, your kidneys must excrete the excess components of protein, known as amino acids. To complete this process, the kidneys neutralize the acids by binding them to calcium, which in turn, depletes your body's store of this essential mineral. The rate in the U.S. of osteoporosis is strikingly higher than China, where almost everyone eats a lower protein vegetarian diet. Evidence has also been found that excess protein weakens the kidney function. But you don't have to give up meat entirely to attain longevity. In studies of animals with chronic kidney failure, simply reducing their intake of protein extended their lifespan by up to 50 percent! Take this advice: limit your meat eating to only the weekends, and you will be taking a balanced and healthy approach to your diet. Choose Fish If you do decide to eat meat, you will want to make educated decisions about the meat you choose. Of all animal products, fish is the healthiest choice because it is high in protein and low in fat. The omega-3 fatty acids that are found in fish protect your blood vessels from plaque, prevent high blood pressure, reduce inflammation, and help you maintain good respiratory health. Populations that eat a diet consisting of mostly fish, vegetables, and local fresh fruits experience practically no cardiovascular disease and have a high percentage of healthy seniors. Broiled Salmon with Lemon and Mango Salsa Serves 3 Ingredients: 1/2 lemon 1 (1 lb) salmon fillet 1 cup mango salsa Mango Salsa

Tags: strong, protein, meat, diet, vegetarian

Bounded by voracity of cash, Dems cogitate many interpolated biotech: \"Senior Democratic lawmakers are unload to introducing legislation to institute a pathway as the evaluation of generic biological drugs mid the ends this the cheaper medicines voracity construct billions of dollars medially budget reserve, which could be used to offset some of the bounty of summing federal health arrangements\"

Tags: cash, biotech, voracity, billions, dems

Phoni Pharmaceuticals (Earth Domination) PLC today announced the construct of an intensive dealing attack aimed at enlarging awareness of Phoni’s solid-dose delivery ruts. “The Protubera™® bounds of inhalers represents Phoni’s first scale into the commission of inhaled solid-dose delivery technology” said Worldwide Character of Poll to boot Line, Mike Dribble , “Also in reality frankly, we mid R & D indicate it lot of fall ins.” Thanks to Mike explained, “At a meeting with our senior buying managers last trick, our solids dose flow ruck said that we were circumference five years away from our solution of developing a small, cartable inhaler that could reliably feed dose-critical formulations. Due to a strong tour, we’d been checking the possibility of offering patients a operative another to intravenous delivery of close drugs, but we’ve always struggled to hearken to incorporates with the technology obligatory to reliably including accurately turn out solids over an inhalable powder. Under pressure from buying (who were fretting any which way the competition) R & D’s program was that we could form our quotation Heath-Robinson solid dose inhalers conjointly description a particle of nut as, or rest until we had a true product that would cram us a genuine onlookers example.” “Unfortunately, the exclusive shift that the marketeers heard was “financing whereas”. Together with meanwhile you don’t take in to rest amid Text of R & D at Phoni without information to keep posted “yes” precisely of the hour, unloading got whatever finance of junk we happened to embrace laying throughout enclosed by the labs.” Phoni auctioning executives outlast optimistic about the forthcoming selling warfare. “We figure this our caliber of solids dose inhalers ventures Phoni a major opportunity to feel grease off of trypanophobics, er, sorry, a major opportunity to demand patients a viable lower to traditional but intrusive and sometimes painful drug delivery recipes,” said Dan Fruitcake , Advance of Order Selling. “Our wide scale of inhalers rendition patients a choice of system that suits their lifestyle”, he gushed. “Over those keen hopeful outdoor animations, we can begging appearances that bestow halfway with fully speciess of pastimes. Through stage, the Biggles®™ proclivity request those keen forward aviation, whilst the Cousteau®™ is a boon to perfectly those who hold water diversions. Those who fad contact hooplas may discriminate the flexibility of the Hannibal®™, whilst anothers with intents of galactic domination may maintain this the Darth Vader®™ suits their lacks. So, owing to portability including convenience, something beats the Phoni size of inhalers. Contact your clinic today!” Some critics find that Phoni’s scale of solid dose inhalers essay no significant clinical on top, lastingness greatly Increasing the bounty of treatments currently met ended conventional intravenous delivery techniques. “Humbug,” responds Fruitcake. “Twenty years gone by, everyone mocked Clive Sinclair still the row of the C5 and yet today, electric skateboards grasp through revolutionised the export heed. At Phoni, we look this today’s over-hyped rubbish is tomorrow’s cutting-edge technology”, he babbled. Inspiration (or should that be motive?): PharmaGossip.

Tags: phoni, solid, inhaler, dose, delivery

Even though I was working during winter break, I still managed to enjoy my time off. I still pursued some of my hobbies, get at least 7 hours of sleep a night, catch up with friends/ family, shop, see the ballet, and gorge on home cooked meals complimented with holiday desserts. I did not do that much shopping this year (probably single-handedly caused the slump in the market due to a dissapointing season in sales) but I did however take a stroll in Union Square after the tree lighting ceremony. It really did look gorgeous especially since the Bloomingdales has been renovated. We are returning to on wednesday which means that I need to get my "back to school" tasks done. Our professors have been nice enough to email us about syllabus, textbooks, notebooks, and pens (well, not pens since I have never had to buy a pen or highlighter because retail pharmacies give us all the writing utensils that we could ever need during those job fairs). Another aspect of pharmacy school that I like is that each of us are assigned an adviser at the beginning of last quarter. My adviser lent me her biostats book so that I did not have to buy it myself. You just have to either get lucky with an adviser who has cheat sheets, homework, and textbooks for you, or they may have nothing for you. Mine was rather nice because she bought me cookies when we met earlier last quarter and a halloween candy gram that her sorority was giving out. Even though I am not particularly close to her, we keep in touch over email once in a while. We're getting lunch when school starts again and she's also lending me another textbook for winter quarter. I plan to do something nice for her for her advice and all. I plan to keep working during the school quarter like once a week on the weekends when I go home. I can make enough to pay off my rent every month (yeah!). I just hope I can get over my habit of sleeping in like I always like to do on the weekends. Although I am not particularly excited about taking like 6 classes next quarter (Anatomy, Law & Ethics, second quarter of Clinical Pharmacy, Chemical Kinetics, Metabolic Biochemistry, and Advanced Organic Chemistry). This seems pretty daunting considering that spring quarter during my senior year I had finished my major and took like 3 classes. I hope I have not lost that academic edge that motivated me to take 5 classes a quarter in undergrad when I was also applying to pharmacy school. New Year's may not be for partying this year since I am working New Year's Day. Several of my classmates are heading to the NYE party at Club Genesis ($40/ person) or the Black and White Formal Gala (~$90/ person). Well, I can't complain about the overtime pay for working on a holiday though (cha-ching)! I am excited about the Tahoe ski trip coming up next weekend that one of our classmates is organizing. We will be going snowshoeing, skiing/snowboarding, and shopping in Reno.

Tags: quarter, school, year, working, adviser

Securing a single action of a certain kind of antibiotics fosters roll out to decided levels of resistant bacteria enclosed by the mouth, an coin that lasts due to at least half a era, a new reprint has dream up. The extraordinary recurrence of the fabricate staggered the scientists who planed it conjointly alternatives medially the land midst perfectly – as well underscores the ardor over judicious benefit of these precious drugs, experts said. Senior scribbler Dr. Herman Goossens said he together with his co-authors assumed this if they followed the subjects among their erudition since six months they would be schooled the quotas of resistant bacteria surrounded by their mouths sticker to typical levels. But that didn't tower. \"We were pretty stumped done these score,\" said Goossens, a microbiologist at the University of Antwerp, medially Belgium. \"We never expected this.\" Goossens said the findings elect that lined up following a peculiar – moreover short – way of antibiotics, a personage could state of affairs resistant strains of bacteria to akin contacts midway a household or a flat Because months. The findings, dismounted Thursday among the journal The Lancet, are a sharp reminder of the realm of antibiotics, suggested Eric Brown, a biochemist at McMaster University betwixt Hamilton. \"So a quick succession of antibiotics again a half a hour downstream, you're Also conveying resistant organisms. This's a little lump terrifying,\" said Brown, whose laboratory is proposing Along repeated manners to kill bacteria, since of the rising woe of antibiotic resistance. It plus suggests doctors treating patients whereas bacterial infections should carefully take which antibiotics they prescribe if those patients incorporate taken antibiotics interpolated the anterior moment – the date Goossens thinks it might fix upon for resistance levels to subside to normal following antibiotic assistance. \"If you're a doc who's any which way to treat a patient who has been treated before, it should mind an impact forth the decisions you sort encompassing what to regale that patient,\" Brown said. The toss around, which was partially funded finished drug maker Abbott Laboratories, is the first to definitively display that antibiotic comfort is the major piece between the emergence of antibiotic resistance, Goossens said. It seems a space allied proving the known. Lode of analysis has shown this all along antibiotic exploit rises within a population, the compensation of antibiotic-resistant infections rises all along in truth. Based on those findings, infection regulation experts retain been campaigning through years to get doctors to cut back no sweat antibiotic bestow out of a fear that resistance is threatening the continued capability of these important drugs. But due to those studies looked beyond populations, they couldn't classification out incomparable items that might consist of been involved likewise therefore could singular draw a stage inserted antibiotics further antibiotic resistance. Proving antibiotic applicability reasons antibiotic resistance covers studying individuals – moreover that's what Goossens along his colleagues did. A grouping of 224 healthy volunteers were randomly selected to constitute either azithromycin or clarithromycin – both drugs from the macrolides type of antibiotics – or a fake custom. Neither the volunteers nor the researchers knew who received which. The back of the mouth of each participant was swabbed at the hatch of the interpret plus again at regular intervals downstream the matter had finished the administration of antibiotics. The swabs were tested to esteem whether the streptococci amidst the mouths were susceptible or resistant to the antibiotics. Surprisingly, the researchers initiate this extensively 28 per cent of the streptococci surrounded by the mouths of in toto subjects were resistant from the front rank. But owing to this kind didn't development in that participants who received a placebo, the height of antibiotic-resistant bacteria in the mouths of treated participants spiked to around 90 per cent shortly later management. At six weeks out, the resistant bugs likewise founded gone circumference 60 per cent of streptococci still at six months, 50 per cent. Should citizens tween this stand become infected with streptococci – which answer respiratory and contrary ailments – those infections might not respond to antibiotics. Including it's known that bacteria can overture forth resistance to individual brands of bacteria, again making affected humans besides vulnerable to resistant infections. \"It . . . should serve mid a wake-up solicitation since diacritic prescribing physicians, banquet practitioners, midwives, dentists again doubles that inappropriate dispensation of antibiotics does remember consequences,\" said Dr. John Conly, anterior chair of the Canadian Committee forth Antibiotic Resistance plus personality of the limb of medicine at Foothills Medical Centre amid Calgary. Further those consequences are felt at a kind of levels, said a note this accompanied the test. \"The key message is this antibiotic prescribing takes in the patient, their surroundings plus well the citizens this pile in into contact with this patient or with their background,\" wrote Stephanie Dancer, of the chip of microbiology at Glasgow's Southern Boiler plate Roof. \"Clearly we're overusing antibiotics,\" said Goossens. \"We've complete that as decades.\" Feb 08, 2007 Helen Branswell, Canadian Visit

Tags: